Results 141 to 150 of about 5,742 (217)

A novel antituberculosis agent exhibits potent clinical efficacy and good safety profile: an open-label, randomized-controlled, multicenter, phase 2a trial. [PDF]

open access: yesSignal Transduct Target Ther
Chu N   +15 more
europepmc   +1 more source

Increasing Antimicrobial Resistance to First-Line Therapies in Chronic Endometritis: A 2020-2024 Cross-Sectional Study. [PDF]

open access: yesJ Clin Med
Cicinelli E   +10 more
europepmc   +1 more source

Antibiotic Class-Specific Effects on Inflammatory Bowel Disease: Microbiome Disruption, Risk, and Recovery. [PDF]

open access: yesInt J Mol Sci
Rajarathinam B   +12 more
europepmc   +1 more source

<i>In vitro</i> exposure to clofazimine can select for delamanid and pretomanid resistance in <i>Mycobacterium tuberculosis</i>. [PDF]

open access: yesAntimicrob Agents Chemother
Rupasinghe P   +15 more
europepmc   +1 more source

Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025). [PDF]

open access: yesMed Res Rev
Al-Karmalawy AA   +6 more
europepmc   +1 more source

[From ICU to recovery: recurrent pneumonia due to Lophomonas blattarum]. [PDF]

open access: yesRev Med Inst Mex Seguro Soc
Cárdenas-de Luna MJ   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy